EMG
SBBP

Ellington Management Group’s Strongbridge Biopharma plc. SBBP Stock Holding History

Ellington Management Group’s Portfolio SBBP Stock Details SBBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-12,100
Closed -$73K – 752
2018
Q2 		$73K Buy
+12,100
New +$88.5K 0.01% 462

Other funds holding SBBP

CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
HCS
Harvest Capital Strategies San Francisco, California $73.7M AUM 7.47% 1-Year Est. Return

Ellington Management Group's SBBP Position: Q3 2018 in Review

Ellington Management Group sold out of Strongbridge Biopharma plc. (SBBP) in Q3 2018, closing a stake of 12,100 shares — an estimated $73K sold.

Ellington Management Group first reported a position in SBBP in Q2 2018 and held it in 1 quarter. The position peaked at $73K in Q2 2018. 49 funds tracked by Wall St. Rank hold SBBP as of Q3 2018.

  • Ellington Management Group reported no remaining Strongbridge Biopharma plc. position as of Q3 2018 after selling out during the quarter.
  • Ellington Management Group sold 12,100 Strongbridge Biopharma plc. shares in Q3 2018, an estimated $73K.
  • Ellington Management Group first reported a position in Strongbridge Biopharma plc. in Q2 2018 and held it in 1 quarter.
  • Ellington Management Group's Strongbridge Biopharma plc. position peaked at $73K in Q2 2018.
  • 49 funds tracked by Wall St. Rank held Strongbridge Biopharma plc. as of Q3 2018.

Based on Ellington Management Group's 13F filing for Q3 2018, filed 14 Nov 2018.